Terrence Park

Senior Principal Scientist

Terrence joined Centivax with over 20 years of preclinical drug development experience as a research scientist and in vivo operations leader. Most recently, as Senior Manager of In Vivo Operations at Asher Biotherapeutics, he served as lead in vivo scientist for multiple projects, including their clinical-stage molecule etakafusp alfa (CD8-targeted IL-2). Prior to Asher, Terrence spent 13 years at Rinat Neuroscience/Pfizer, where he was the primary in vivo scientist for programs across immuno-oncology, metabolism, and CNS, supporting multiple successful IND filings. He is known for creative problem-solving, rigorous execution, cross-functional collaboration, and a commitment to developing therapies that improve patients' lives.